Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 2Uterine Cervical Neoplasms 1Salivary Gland Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Trastuzumab 3Docetaxel 3Biopsy 3trastuzumab deruxtecan 2pembrolizumab 2Vorinostat 2Taxes 2SS1(dsFv)PE38 2Polymerase Chain Reaction 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Immunohistochemistry 2Gene Expression Profiling 2Flow Cytometry 2zanidatamab 1tipifarnib 1tanespimycin 1spartalizumab 1sargramostim 1pertuzumab 1oncogene protein E7, Human papillomavirus type 16 1neratinib 1entrectinib 1entinostat 1ceralasertib 1alectinib 1aldesleukin 1Specimen Handling 1Ritonavir 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × neratinib × Gynecologic × Clear all
NCT06519110 2024-07-25

CVL009-C2001

Convalife (Shanghai) Co., Ltd.

Phase 2 Not yet recruiting
60 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Salivary Gland Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡